Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2000, p. 3852-3859, Vol. 20, No. 11
Experimental Immunology Branch, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland
20892
Received 3 February 2000/Returned for modification 3 March
2000/Accepted 15 March 2000
T-cell development in the thymus is characterized by changing
expression patterns of CD4 and CD8 coreceptor molecules and by changes
in CD4 and CD8 gene transcription. In response to T-cell receptor (TCR)
signals, thymocytes progress through developmental transitions, such as
conversion of CD4+CD8+ (double-positive [DP])
thymocytes into intermediate CD4+CD8
0270-7306/00/$04.00+0
CD8 Coreceptor Extinction in Signaled
CD4+CD8+ Thymocytes: Coordinate Roles for Both
Transcriptional and Posttranscriptional Regulatory Mechanisms in
Developing Thymocytes

thymocytes, that appear to require more-rapid changes in coreceptor expression than can be accomplished by transcriptional regulation alone. Consequently, we considered the possibility that TCR stimulation of DP thymocytes not only affects coreceptor gene transcription but
also affects coreceptor RNA stability. Indeed, we found that TCR
signals in DP thymocytes rapidly destabilized preexisting CD4 and CD8
coreceptor RNAs, resulting in their rapid elimination. Destabilization
of coreceptor RNA was shown for CD8
to be dependent on target
sequences in the noncoding region of the RNA. TCR signals also
differentially affected coreceptor gene transcription in DP thymocytes,
terminating CD8
gene transcription but only transiently reducing CD4
gene transcription. Thus, posttranscriptional and transcriptional
regulatory mechanisms act coordinately in signaled DP thymocytes to
promote the rapid conversion of these cells into intermediate
CD4+CD8
thymocytes. We suggest that
destabilization of preexisting coreceptor RNAs is a mechanism by
which coreceptor expression in developing thymocytes is rapidly altered
at critical points in the differentiation of these cells.
*
Corresponding author. Mailing address: Experimental
Immunology Branch, National Cancer Institute, Building 10, Room 4B36, Bethesda, MD 20892. Phone: (301) 496-5461. Fax: (301) 496-0887. E-mail:
SingerA{at}mail.nih.gov.
Present address: Vaccinex, L.P., Rochester, N.Y.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»